CBDV Begins Research on Psilocybin with Section 56 Exemption from Health Canada
“Health Canada has granted a Section 56 exemption allowing the Company to develop new analytical methods for psilocybin mushrooms and study their metabolites. CBDV will develop analytical methods for psilocybin…”
The original article can be found at: Delic Labs
Related Articles
As different cannabis products have differing potency levels, knowing the potency of a product is important for determining the correct dosage. Currently, chromatography is used for potency testing of cannabis products. We teamed up with Agilent to show that FTIR spectroscopy can also be used to further enhance these testing processes.
